ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2026
Unrecognized Transmission Risks of Occult Hepatitis B Virus Infection Among Blood Donors in Central Ethiopia.
Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unrecognized Transmission Risks of Occult Hepatitis B Virus Infection Among Blood Donors in Central Ethiopia.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Occult hepatitis B virus infection (OBI) refers to the detection of HBV DNA in blood or liver tissue in individuals who test negative for hepatitis B surface antigen (HBsAg), excluding the early phase of acute HBV infection. This hidden form of infection represents a substantial but frequently underestimated risk to blood transfusion safety, particularly in settings with limited resources. In Ethiopia and other low-income countries, routine screening of blood donors often depends solely on HBsAg tests, which may overlook symptom-free carriers with low viral loads. This study was conducted to estimate the prevalence of OBI among HBsAg-negative blood donors and to assess its potential contribution to undetected HBV transmission in central Ethiopia. Methods: Five hundred and eighty-two plasma samples from HBsAg-negative donors were analyzed. Initial screening for anti-Hepatitis B core antibodies (anti-HBc) was carried out using an enzyme-linked immunosorbent assay (ELISA). Samples that tested positive for anti-HBc were then analyzed for HBV DNA using the Abbott m2000 automated real-time polymerase chain reaction (RT-PCR) system. At the same time, information on sociodemographic characteristics and potential clinical risk factors for HBV exposure was obtained through structured questionnaires. Data were analyzed with SPSS Version 21, and statistical significance was considered at a Results: In this study, screening of 582 blood donors who were negative for HBsAg revealed that 135 (23.2%) donors, or nearly one-quarter, showed evidence of previous HBV exposure through anti-HBc reactivity. Subsequent molecular testing (PCR) identified a small proportion of these individuals carrying HBV DNA, confirming occult infection. Viral loads in all confirmed cases were low. Older donors, particularly those above 35 years of age, demonstrated a markedly higher rate of anti-HBc positivity. Overall, the occurrence of OBI was estimated at 1.7%, or approximately 17 cases for every 1000 blood donations, highlighting a critical gap in the current HBV screening protocol. Conclusion: The findings demonstrate that a notable number of blood donors in central Ethiopia carry occult HBV infection, equivalent to 17 cases per 1000 donations. This indicates a concealed yet important risk of HBV transmission through blood transfusion. These results underscore the need to enhance donor screening protocols by incorporating both anti-HBc testing and nucleic acid testing (NAT) to improve transfusion safety and prevent the spread of undetected HBV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.